Maravai LifeSciences

Offers oligonucleotide synthesis and immunohistochemistry

Maravai LifeSciences

Offers oligonucleotide synthesis and immunohistochemistry

Overview

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including investing in and supporting entrepreneurial life-science companies with expertise, capital, and operational resources. Its products include oligonucleotide synthesis for PCR, next-generation sequencing, and gene editing, as well as immunohistochemistry for cancer research, which scientists use to perform DNA/RNA workflow steps and detect proteins in tissue samples. The company differentiates itself by combining investment and active operational support with access to essential research tools, helping portfolio companies grow and reach researchers faster. Its goal is to catalyze the development of life science companies to advance human health by providing capital, know-how, and core research tools.

Work here?Claim your company

About Maravai LifeSciences

Simplify's Rating

Why Maravai LifeSciences is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

Venture CapitalBiotechnologyHealthcare

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, CA

Founded

2014

Get referred to Maravai LifeSciences

See people who can refer or advise you

Simplify's take

What believers are saying

Third-quarter 2026 revenue rose 10% to $45.9 million, and EBITDA improved to $5.8 million.
Maravai raised 2026 guidance to $212 million-$216 million after 28% mRNA sales growth.
More than 70 discovery mRNA customers joined, and GMP ModTail launches before year-end.

What critics are saying

TriLink still depends on lumpy customer program timing; quarterly revenue swings continue through 2027.
COVID-era commercial CleanCap revenue vanished, exposing TriLink’s dependence on non-pandemic demand.
If mRNA and GMP adoption stalls, Maravai remains a narrow reagents vendor with weak power.

What makes Maravai LifeSciences unique

TriLink’s CleanCap and GMP mRNA tools anchor Maravai’s differentiated nucleic-acid workflow moat.
Cygnus sells essential host-cell-protein and ELISA kits with 71% adjusted EBITDA margins.
Maravai’s China patent protection and in-country sales presence strengthen international IP and distribution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$180M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Debt Funding Comparison Coming Soon

Benefits

Health Insurance
Company Equity
Fertility Treatment Support
Family Planning Benefits
401(k) Retirement Plan
Paid Vacation

Stock Price

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-1%

2 year growth

-1%

Yahoo Finance

Nov 5th, 2026

Maravai raises 2026 revenue guidance to $212M–$216M as mRNA sales jump 28%

Maravai LifeSciences raised its 2026 forecasts after third-quarter revenue rose 10% to $45.9 million. The company now expects full-year revenue of $212 million to $216 million, up from $205 million to $215 million. It lifted its adjusted EBITDA guidance to $40 million–$42 million from $33 million–$35 million. Third-quarter adjusted EBITDA improved by $16.6 million to $5.8 million. Sales of mRNA products at its TriLink unit climbed 28% to $15.3 million. Net loss narrowed to $24 million from $45.1 million a year earlier. Chief executive officer Bernd Brust said Maravai added more than 70 discovery mRNA customers and plans to launch GMP-grade ModTail before year-end. Chief financial officer Raj Asarpota warned that quarterly results may swing with the timing of large orders.

Daily Political

Nov 4th, 2026

What Maravai LifeSciences (MRVI) said on its Q3 earnings call.

What Maravai LifeSciences (MRVI) said on its Q3 earnings call. Posted by Jeff Wilder on Nov 4th, 2026 Maravai LifeSciences (NASDAQ:MRVI) raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at its Cygnus business. The life sciences company reported revenue of $45.9 million for the quarter. Its net loss before non-controlling interests narrowed to $24 million from $45.1 million a year earlier, while adjusted EBITDA improved by $16.6 million to $5.8 million. CEO Bernd Brust said the results reflected higher revenue, a favorable product mix and benefits from changes to the company's operating model. Adjusted gross margin expanded by more than 1,700 basis points from a year earlier to 57.7%. mRNA demand drives growth. Revenue at TriLink, which represented 62% of company sales, rose 12%. Within the segment, mRNA revenue increased 28% to $15.3 million, with good manufacturing practice, or GMP, consumables up 30% and discovery mRNA up 27%. Specialty chemistry revenue declined 4% to $11 million because some large orders from the prior-year quarter did not recur. Contract development and manufacturing, or CDMO, revenue rose 8% to $2 million. Maravai had no high-volume CleanCap revenue from commercial-phase COVID-19 vaccine programs during the quarter. Cygnus revenue grew 8%, marking its sixth consecutive quarter of year-over-year growth. The segment generated $12.5 million in adjusted EBITDA, with a margin of 71%, CFO Raj Asarpota said. He cited steady demand for host-cell protein and ELISA kits and strength in China, Korea and India. Maravai reported a basic and diluted loss of $0.09 per share, compared with a loss of $0.18 a year earlier. Its adjusted loss narrowed to $0.03 per share from $0.08. The company ended the quarter with $73 million in cash and $147.2 million in debt. Higher outlook, with order timing in focus. Management raised its full-year revenue guidance to $212 million to $216 million from $205 million to $215 million. It also lifted its adjusted EBITDA forecast to $40 million to $42 million from $33 million to $35 million and expects adjusted gross margin to expand by more than 1,600 basis points for the year. Asarpota cautioned that revenue and adjusted EBITDA can vary from quarter to quarter because large GMP consumables and CDMO orders depend on customer program timing. He said the guidance range allows for variability in when expected orders convert to revenue. Brust said the company expects fourth-quarter GMP volumes to be substantially higher than in the third quarter, though growth against a strong fourth quarter in 2025 may not be material. He expects full-year GMP growth of more than 20% and said the GMP pipeline for 2027 could be weighted toward the second half because of customer program timing. Product launches and customer pipeline. Maravai expects to launch GMP-grade ModTail before year-end. More than 180 customers were actively using the technology at the end of the third quarter, up from 125 at the end of the second quarter, Brust said. In response to an analyst's question, Brust said he expects some ModTail customers to enter early-stage clinical studies in 2027 but would not expect "massive dollars" from GMP ModTail next year. He said customers are working through drug discovery and want GMP material available if their programs reach the clinic. The company added more than 70 discovery mRNA customers in the quarter. Four discovery customers moved to clinical-stage GMP work, bringing year-to-date conversions to 10 and exceeding Maravai's initial full-year target of nine. Brust said the company was supporting more than 50 GMP customers in 2026, with an estimated two to three clinical programs per customer on average. Maravai also recently established an in-country sales presence in China. Brust said the company is reassessing its approach to TriLink in the country after receiving additional patent protection there. Cygnus has already seen strong growth in China this year, he said, and the new presence is intended in part to support dealers and improve customer interactions. About Maravai LifeSciences (NASDAQ:MRVI). Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development. Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.

The Markets Daily

Nov 3rd, 2026

Maravai LifeSciences (MRVI) projected to post earnings on Wednesday.

Maravai LifeSciences (MRVI) projected to post earnings on Wednesday. Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Maravai LifeSciences to post earnings of ($0.0563) per share and revenue of $43.56 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET. Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The business had revenue of $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. On average, analysts expect Maravai LifeSciences to post ($0.18) EPS for the current fiscal year and ($0.13) EPS for the next fiscal year. Maravai LifeSciences trading up 5.0%. NASDAQ MRVI opened at $7.55 on Tuesday. The firm's 50 day moving average price is $7.47 and its two-hundred day moving average price is $5.25. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. Maravai LifeSciences has a twelve month low of $2.55 and a twelve month high of $9.42. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -14.42 and a beta of 0.54. Wall Street analysts forecast growth. MRVI has been the subject of a number of research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. UBS Group upped their target price on Maravai LifeSciences from $2.50 to $8.00 and gave the company a "neutral" rating in a report on Wednesday, September 9th. Wells Fargo & Company increased their price target on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Wall Street Zen cut shares of Maravai LifeSciences from a "buy" rating to a "hold" rating in a report on Saturday, August 29th. Finally, TD Cowen began coverage on shares of Maravai LifeSciences in a research report on Monday, October 5th. They set a "buy" rating and a $9.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of "Moderate Buy" and a consensus price target of $7.38. About Maravai LifeSciences. Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development. Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing. Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.

MarketBeat

Aug 25th, 2026

Maravai LifeSciences (NASDAQ:MRVI) sets new 52-week high - still a Buy?

Maravai LifeSciences (NASDAQ:MRVI) sets new 52-week high - still a Buy? August 25, 2026 Key points. * Maravai LifeSciences shares hit a new 52-week high, reaching $8.87 and closing around $8.75, up 3.3% on the session. The stock's market capitalization is approximately $2.26 billion. * Analyst sentiment remains mixed, with two Buy and two Sell ratings producing a consensus "Hold" rating and a $6.25 price target - well below the current share price. * Maravai exceeded quarterly expectations, reporting an adjusted loss of $0.02 per share versus the expected $0.04 loss and revenue of $51.44 million versus estimates of $48.67 million. However, the company remains unprofitable, with negative margins and analysts forecasting a full-year loss. * Five stocks to consider instead of Maravai LifeSciences. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.87 and last traded at $8.7450, with a volume of 1027230 shares traded. The stock had previously closed at $8.43. Analyst upgrades and downgrades. Several equities analysts have weighed in on MRVI shares. Weiss Ratings upgraded Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 29th. UBS Group reissued a "reduce" rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. Wall Street Zen raised Maravai LifeSciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Finally, Wells Fargo & Company increased their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $6.25. Maravai LifeSciences trading up 3.3%. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -16.76 and a beta of 0.63. The company has a 50-day moving average price of $6.35 and a 200-day moving average price of $4.62. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49. Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The business had revenue of $51.44 million during the quarter, compared to analysts' expectations of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. Research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year. Insider buying and selling at Maravai LifeSciences. In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company's stock. Institutional trading of Maravai LifeSciences. A number of hedge funds have recently bought and sold shares of MRVI. Jane Street Group LLC increased its holdings in shares of Maravai LifeSciences by 1,463.1% during the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company's stock worth $841,000 after purchasing an additional 356,067 shares during the period. Creative Planning grew its position in Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company's stock worth $280,000 after buying an additional 38,450 shares in the last quarter. Rhumbline Advisers grew its position in Maravai LifeSciences by 20.3% during the second quarter. Rhumbline Advisers now owns 195,272 shares of the company's stock worth $471,000 after buying an additional 32,940 shares in the last quarter. Prudential Financial Inc. bought a new position in Maravai LifeSciences during the second quarter valued at about $36,000. Finally, Invesco Ltd. increased its stake in Maravai LifeSciences by 16.8% during the second quarter. Invesco Ltd. now owns 282,192 shares of the company's stock valued at $680,000 after acquiring an additional 40,495 shares during the period. 50.25% of the stock is owned by institutional investors. Maravai LifeSciences company profile. Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Maravai LifeSciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list. While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Business Wire

Jun 23rd, 2026

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...

Recently Posted Jobs